Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Recs

0
Player Avatar SkepBioInvestor (92.06) Submitted: 12/18/2012 5:46:10 PM : Outperform Start Price: $3.07 VICL Score: +17.60

Make no mistake, A7 will fail, but this is an opportunistic pick ahead of a likely run-up into data in 2H 2013. Look at CLSN and its impressive run-up, twitter cheerleaders included.

Featured Broker Partners


Advertisement